Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Vicore Pharma Holding ABNASDAQ: VCRE

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation outflow grows to SEK 0

Q2 FY2026 stock-based compensation was SEK 0, compared with SEK 0 a year earlier. Trailing-twelve-month stock-based compensation was -SEK 286.79K.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near SEK 0 or moves back toward the trailing-twelve-month quarterly average of -SEK 71.7K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
SEK 0— QoQ
Last fiscal yearDec 2025
SEK 0— YoY
LTMJun 2026
-SEK 286.79K-324.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

SEK · from the cash flow

Latest · FY2025
0 SEK
Year-over-year change
—

Stock-Based Compensation vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -324.0% is the lowest of 2, against a peer median of +126.3%.
  • Stock-based compensation amounts to 21.6% of revenue for VCRE, versus a peer median of 12.2%.
VCRE Competitors
Stock-Based Compensation for VCRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LQDALiquidia CorporationLTM Jun 2026$54.95M USD+126.3%+46.9%12.2%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 286.79K SEK-324.0%—21.6%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —+126.3%+46.9%12.2%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.78M)(290.73M)(321.51M)(194.19M)(452.39M)
Depreciation & Amortization397.75K3.61M3.42M2.24M0
Deferred Income Tax00000
Stock-Based Compensation(172.79K)0000
Change in Working Capital(37.59K)(20.94M)(10.65M)(1.84M)40.81M
Accounts Receivables(37.59K)(1.6M)(4.28M)(35.6M)(3.08M)
Inventory00000
Accounts Payables00000
Other Working Capital0(19.34M)(6.36M)33.77M43.89M
Other Non-Cash Items(231.23M)8.13M79.15M28.84M35.84M
Operating Cash Flow(263.82M)(299.92M)(249.58M)(164.95M)(375.74M)
Capital Expenditures0(3M)000
Acquisitions (Net)00000
Purchases of Investments(76.61M)0(199.04M)(64.81M)(983.95M)
Sales of Investments69.64M77M54.58M213.85M383.45M
Other Investing Activities00000
Investing Cash Flow(6.96M)74M(144.46M)149.04M(600.51M)
Debt Repayment00000
Common Stock Issued316.8M200M500.41M882.14M455.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(237.78K)(12.96M)(29.55M)(48.08M)(24.55M)
Financing Cash Flow316.56M187.04M470.86M834.06M430.54M
Effect of Forex Changes(26.64M)1.48M04.23M(32.16M)
Net Change in Cash2.3M(37.4M)76.82M822.38M(577.85M)
Free Cash Flow(263.82M)(302.92M)(249.58M)(164.95M)(375.74M)

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.